The plasma concentration of lipoprotein (a) [Lp(a)] is correlated with the risk of atherosclerosis. It is a lipoprotein particle consisting of apoprotein (a) [apo(a)], a protein showing considerable amino acid sequence identity with plasminogen, bound to low-density lipoprotein. The apo(a) portion of Lp(a) was recently shown to have serine-proteinase-type amidolytic activity and to be able to degrade the adhesive glycoprotein fibronectin. To characterize this enzyme activity further, we used chromogenic peptide substrates and inhibitors. Of the substrates tested, those with arginine at the scissile bond [N-a-benzoyl-L-Arg p-nitroanilide (pNA), N-a-benzoyl-Ile-Glu-Gly-Arg-pNA, N-a-benzyloxycarbonyl-Arg-GlyArg-pNA] gave the highest hydrolysis rates. Synthetic substrates with plasmin specificity (Val-Leu-L-Lys-pNA and ValPhe-L-Lys-pNA) were not hydrolysed by Lp(a). Neither tissue plasminogen activator nor urokinase had any effect on the enzyme activity. The addition of antibodies to these plasminogen activators did not inhibit the enzyme activity of Lp(a). Inhibition experiments with phenylmethanesulphonyl fluoride, carbodi-imide, dichloroisocoumarin and competitive peptide inhibitors demonstrated that Lp(a) has enzyme activity that closely resembles that of seine proteinases. Whether this serine-proteinase activity of Lp(a) plays any role in the genesis of atherosclerosis remains to be established.
INTRODUCTION
The serum concentration of lipoprotein (a) [Lp(a)] is an important independent risk factor for coronary heart disease [1] [2] [3] . Lp(a), first described by Berg [4] , represents a quantitative genetic trait [5] which is associated with a size polymorphism of Lp(a) [6] . It is a lipoprotein with many physical and chemical properties in common with low-density lipoproteins (LDL) . It has a similar lipid composition to, but a higher density and carbohydrate content than, LDL [7, 8] . The protein moiety consists of apolipoprotein B (apoB) and the (a) protein [apo(a)] [8, 9] . From the Lp(a) particle, apo(a) can be dissociated under reducing conditions [10] . Apo(a) displays genetically determined size heterogeneity, and different forms with molecular masses ranging from 280 to 710 kDa have been reported [11] . Utermann et al. [12] demonstrated that this size heterogeneity is controlled by a series of autosomal alleles at a single locus [13, 14] closely linked to the plasminogen locus on chromosome 6. Recently, the complete DNA sequence and the deduced amino acid sequence of apo(a) have been elucidated [15, 16] . A comparison of apo(a) and plasminogen has revealed a striking sequence similarity between these two proteins. Structures showing sequence identity with the plasminogen elements termed kringle 4, kringle 5 and a C-terminal proteinase region are all present in apo(a). The proteinase domain of apo(a) has 88 % amino acid sequence identity with plasminogen and, furthermore, the catalytic triad (Asp-His-Ser) essential for the proteolytic activity of serine proteinases is retained in apo(a) [15, 17] . Plasminogen is an inactive zymogen and belongs to a family of proteins which include regulatory proteinases of the fibrinolytic and blood-coagulation systems. After being cleaved by tissuetype (t-PA) or urokinase (u-PA) plasminogen activators to form active plasmin, it is a protein essential for the lysis of blood clots [18] . In apo(a) the amino acid corresponding to the arginine at which the activating cleavage ofplasminogen occurs is substituted by a serine residue, a mutation that has been considered to result in an inactive-proteinase region in apo(a) [15, 19] . To our knowledge there has been only one early report describing enzyme activity associated with Lp(a) [20] . Recently Lp(a) has been shown to bind to, and degrade, human plasma fibronectin [21] . The proteolytic activity of Lp(a) was localized to apo(a) and was of the serine-proteinase type. On the basis of experiments with chromogenic peptide substrates and serine-proteinase inhibitors, we now describe some characteristics of this enzymic activity.
EXPERIMENTAL Materials
Chemicals. Sepharose 4B and Heparin-Sepharose CL 6B were from Pharmacia Fine Chemicals, Uppsala, Sweden. Dithioerythritol (DTE), dithiotreitol (DTT) and /8-mercaptoethanol were purchased from E. Merck, Darmstadt, Germany. Trypsin was obtained from Sigma Chemical Co., St. Louis, MO, U.S.A. All other reagents were of the highest available grade.
Inhibitors. Phenylmethanesulphonyl fluoride (PMSF), trypsin inhibitor (from soybean, type I-S), leupeptin, N-ethylmaleimide (NEM) and l-ethyl-3-(3-dimethylaminopropyl)carbodi-imide (EDAC) were purchased from Sigma; aprotinin (Trasylol) was a product of Bayer, Leverkusen, Germany; Tos-Lys-CH2Cl, tosyl-lysylchloromethane ('TLCK'); 3,4-dichloroisocoumarin (DICC) and (4-amidinophenyl)methanesulphonyl fluoride (APMSF) were obtained from Boehringer, Mannheim, Germany; [l,3-3H]di-isopropyl fluorophosphate (iPr2P-F) was purchased from New England Nuclear Co., Boston, MA, U.S.A.
Substrates. Ph-Ile-Glu-Gly-Arg-pNA (where Ph is N-abenzoyl and pNA is p-nitroanilide) (S-2222), Val-Leu-Lys-pNA (S-225 1), Val-Phe-Lys-pNA (S-2390), Glu-Pro-Val-pNA (S-2484), N-a-Cbz-Arg-Gly-Arg-pNA (where Cbz is benzyloxycarbonyl) (S-2765) and Pro-Phe-Arg-pNA (S-2302) were obtained from Kabi Diagnostica, Stockholm, Sweden; N-a-benzoyl-L-Arg p-nitroanilide (L-BAPA), tosyl-L-Arg methyl ester (L-TAME) and tosyl-Gly-Pro-Lys-pNA (Chromozym PL) were purchased from Boehringer.
Antisera. Goat anti-[human tissue plasminogen activator (t-PA)] (IgG fraction) and goat anti-[human urokinase (U-PA)] (IgG fraction) were obtained from Biopool, Umea, Sweden.
Methods
Isolation of lipoprotein (a). Plasma from healthy donors with Lp(a) concentrations of 100-150 mg/dl was obtained by plasmapheresis. Lp(a) was isolated as described [22] by sequential ultracentrifugation [23] followed by gel filtration on a Sepharose 4B column (2.5 cm x 100 cm) eluted with phosphate-buffered saline (PBS). To obtain apo(a), Lp(a) was reduced with 10 mM-DTE at 25°C for 1 h and apo(a) separated by centrifugation in a 1.02-1.18 g/ml KBr density gradient [24] or by heparinSepharose chromatography after reduction with 10 mM-DTT at 37°C for 2 h [25] .
Determination of amidolytic activity. The amidolytic activities of Lp(a) and apo(a) were determined using chromogenic peptide substrates. The substrates S-2222, 2251, 2390, 2765 and L-BAPA were dissolved in distilled water, S-2484 in 8 % dimethyl sulphoxide (DMSO) and L-TAME and Chromozym PL in 100 mmTris/HCI buffer, pH 8.0. In a typical assay, 650 u1 of 100 mmTris/HCl buffer, pH 8.0, and 100 1l of purified Lp(a) solution were added to a cuvette, mixed and preincubated for 5 min at 25 'C. To initiate the reaction, 200 ,ul of substrate was added and the increase in absorbance at 405 nm due to liberated 4-nitroaniline was measured in a Shimadzu UV-260 spectrophotometer. The results are presented either as relative absorbance units or as catalytic units (,umol/min) using the linear millimolar absorption coefficient of 1.02 litre-mmol-' mm-' for 4-nitroaniline, which is in accordance with the values for pnitroaniline at 405 nm. The coefficient given by the peptide substrate manufacturer (Kabi), 1.27 litre-mmol-1 mm-', was determined at a wavelength of 316 nm [26] . The L-TAME reaction was monitored at 247 nm.
Inhibition of amidolytic activity. The inhibitor stock solutions were prepared in distilled water, ethanol or DMSO. The final concentration of organic solvent in the assays did not exceed 1.5 % (v/v). In a typical inhibition experiment purified Lp(a) in 100 mM-Tris/HCl buffer, pH 8.0, was preincubated with different concentrations of inhibitor for 15 min at room temperature.
Thereafter the reaction was initiated by adding substrate and monitored for 10 min.
Other methods. Lp(a) assay is a solid-phase two-site immunoradiometric assay (IRMA) using two monoclonal antibodies directed toward different epitopes on apo(a) [27] . The coefficients of variation were 4.5 % (intra-assay) and 4.9 % (inter-assay). The standard curve range was 15-840 ug of Lp(a)/ml. ApoB was measured with an immunoturbidometric assay. The standardcurve range was 0.2-2.8 mg of apoB/ml (Orion, Helsinki, Finland). Cholesterol was measured by an enzymic method [28] . Protein was assayed according to Lowry et al. [29] , with BSA as standard. PAGE was performed in 2-16% gradient slab gels using a Tris/HCl/borate electrophoresis buffer system as described by the manufacturer (Pharmacia, Uppsala, Sweden).
RESULTS
Lp(a) was isolated from plasma by a combination of ultracentrifugation and gel filtration on Sepharose 4B. When the fraction of density 1.05-1.12 g/ml was subjected to gel filtration, the elution pattern shown in Fig. 1 was obtained. The Lp(a) lipoprotein eluted as a symmetrical peak well resolved from highdensity lipoprotein (HDL). The amidolytic activity determined from the fractions with the synthetic substrate S-2765 paralleled the Lp(a) concentration in these fractions. Thus the specific amidolytic activity eluted between 225 and 285 ml was 3.4 + 0.46 ,umol/min per mg of Lp(a).To study whether the amidolytic activity of Lp(a) resided in the apo(a) portion, this was isolated. When Lp(a) was subjected to density-gradient ultracentrifugation without prior reduction, the amidolytic activity could be demonstrated at a density of about 1.07 g/ml (Fig. 2a) . The same density fractions also contained the Lp(a) protein. When Lp(a) that had been incubated under reducing conditions was centrifuged, cholesterol and apoB (not shown) could be demonstrated at a density of 1.04-1.05 g/ml, whereas the major portion of apo(a) and the amidolytic activity was measurable in the bottom fractions (Fig. 2b) . Isolation of apo(a) using heparin-Sepharose chromatography (Fig. 3) also demonstrated that the amidolytic activity resides in the apo(a) portion of Lp(a).
To characterize the amidolytic activity of Lp(a), chromogenic peptide substrates were used. The rate of hydrolysis, using S- proportional to the amount of Lp(a) added to the assays (Fig. 4) using S-2765 as a substrate) was approx. one-tenth that of trypsin. The plasmin substrates, S-2251 (results not shown) and S-2390 were not hydrolysed by Lp(a) (Fig. 4) . The addition of t-PA (2 ,ug/assay) or u-PA (20 units/assay) had no significant effect on the Lp(a) proteinase activity (results not shown). Neither did the addition of anti-t-PA or anti-u-PA inhibit the Lp(a) proteinase activity (Table 2) . Polyclonal antibodies to apo(a) did not inhibit the Lp(a) amidolytic activity. The inhibition of apo(a)
Vol. 274 . It is probable that the lack of antibody effect on Lp(a) amidolytic activity is due to the shielding effect of the LDL part of the particle, and the weak inhibitory effect on apo(a) may be either due to the rather low affinity of anti-Lp(a) antisera toward the apo(a) or due to antisera binding to catalytically non-essential regions on apo(a). In addition, anti-(Factor Xa) antibodies at increasing concentration/assay did not inhibit Lp(a) enzyme activity. Further, by immunoblotting the Lp(a) samples with anti-(Factor Xa) antibodies we could not detect any Factor Xa antigen in our Lp(a) preparations.
To study the mechanism underlying the amidolytic activity of Lp(a), reagents known to interfere with the catalytic triad (AspHis-Ser) of serine proteinases were used. When the competitive peptide inhibitors leupeptin and aprotinin (known to block the active site of several serine proteinases) were used, leupeptin (10 /ug/ml) and aprotinin (0.5 mg/ml) gave 40 % and 26 % inhibition respectively. The soybean trypsin inhibitor, which at the concentration used (0.1 mg/ml) effectively inhibits trypsin, had no effect on the amidolytic activity of Lp(a).
The carboxy-group reagent EDAC, a hydrophilic carbodiimide, inhibited the amidolytic activity in a concentration- (Fig. Sa) . The inhibition followed first-order reaction kinetics. Of reagents known to react with histidine, DCIC was the most effective inhibitor. Half of the activity was already abolished at 0.22 mM-DCIC (Fig. 5b) . The inhibition did not follow first-order kinetics, but gave a relatively linear response to increasing DCIC concentrations. Another histidine-specific reagent, Tos-Lys-CH2Cl, inhibited the enzyme only slightly (88 % residual activity at 10 mM-Tos-Lys-CH2Cl; result not shown). Inhibition experiments with [3H]iPr2P-F indicated that the inhibitor did not bind to Lp(a), neither did it cause inhibition of enzyme activity, as measured with the synthetic substrate S-2765. The seine-specific reagent PMSF inhibited the amidolytic activity of Lp(a) in a concentration-dependent manner (Fig. 5a) . At 1.7 mm a 50 % inhibition occurred, and at 7 mM-PMSF, only 16% residual activity remained. The addition of an amidino group to PMSF abolished the inhibitory effect. In addition, the inhibition of the amidolytic activity of purified apo(a) was tested with DCIC, PMSF and EDAC under the same experimental conditions as with Lp(a). As compared with the control activity [the 100 % value for the apo(a) amidolytic activity was 3.7 ,umol of p-nitroaniline liberated/min; S-2765 used as a substrate] the remaining activities with these inhibitors were as follows: DCIC (0.3 mM), 16 %; DCIC (0.6 mM), 3 %; PMSF (5 mM), 200 , and To obtain data on the kinetics of Lp(a) amidolytic activity, the Km (apparent) and Vmax were determined with S-2765 as a substrate (at various concentrations) and a fixed amount of Lp(a) ( Table 3) . The effect of different inhibitors on these kinetic parameters was also evaluated. Km (apparent) did not significantly change in the presence of inhibitors, but there was a clear reduction in Vm.. . This suggests a non-competitive type of inhibition of Lp(a) amidolytic activity.
DISCUSSION
As Lp(a) has been reported to be an independent risk factor for coronary heart disease [1] [2] [3] 30] , our observation that apo(a) has serine proteinase-type amidolytic activity may be of importance in revealing the mechanism(s) whereby Lp(a) is atherogenic. The striking sequence similarity between plasminogen and apo(a) [15] , especially in the proteinase region, suggests that apo(a) might be proteolytically active. By contrast, however, at the site where plasminogen is activated to plasmin, the arginine residue is replaced by a serine residue in apo(a), suggesting that apo(a) does not have proteolytic activity [15, 19] . Only two reports describe amidolytic activity, whereas others do not [15, 19] . The reason for this discrepancy may be explained by the difference in substrate specificity between plasmin and apo(a). Plasmin preferably cleaves substrates at the carboxy end of lysine [31, 32] . We demonstrate that Lp(a) does not hydrolyse synthetic 'plasmin substrates' which have lysine at the scissile bond (S-2251 and S-2390) and that the activators of plasminogen, t-PA and u-PA, do not significantly affect the amidolytic activity of apo(a). These observations agree with previous studies reporting no plasmin-like activity [15, 19] . However, using substrates containing arginine at the scissile bond, Lp(a) displays amidolytic activity. This specificity is similar to that reported by Jurgens et al. [20] , who used L-TAME and L-BAPA substrates in their assays. Serine proteinases share a common catalytic mechanism, and their different specificities have been shown to arise from amino acid differences in the substrate-binding regions [17, 33] . The residues which determine the substrate specificity, are located at positions -6 (at the bottom of the substrate-binding pocket), + 15 to + 17, and + 25, relative to the serine at the active site [17] . A serine proteinase which also displays specificity for arginine is granzyme A, a serine proteinase found in granules of cytolytic T-lymphocytes [34] . In apo(a), aspartic acid at -6 is the same as that found in granzyme A.
To demonstrate that apo(a), besides having sequence identity with, also functions as, a serine-proteinase-type enzyme, we evaluated different proteinase inhibitors. Reagents known to react with catalytically essential amino acids and peptides which competitively bind to the active site have previously been employed to elucidate the structure and function of the catalytic triad Ser-His-Asp characteristic for serine proteinases [17, [35] [36] [37] . It has been demonstrated that the amidolytic action of serine proteinases depends on the activation of the catalytic serine residue. In this process a histidine residue and the carboxy group of aspartic acid participate [17, 38, 39] . Our inhibition experiments revealed that serine-, histidine-and carboxylic-group-specific reagents, PMSF, DCIC and EDAC respectively, inhibited the amidolytic activity of purified Lp(a) and apo(a), observations which indicate that these residues are involved in catalysis. The inhibition with PMSF and EDAC followed first-order reaction kinetics, but the kinetics with DCIC were different. The reason for this is probably due to the two-step reaction pathway characteristic for DCIC. Harper et al. [40] reported that DCIC first acylates the serine at the active site, forming a reactive acyl chloride, which then forms an ester bond with a histidine at or near the active site.
Substrate-specificity and inhibition experiments on human plasma Lp(a) showed that Lp(a) and purified apo(a) 'prefer' substrates which have arginine at the scissile bond and that serine, histidine and carboxy groups are essential for the hydrolysis of these chromogenic peptide substrates. These findings demonstrate that human Lp(a) is also functionally closely related to serine-proteinase enzymes. The proteinase activity is localized to the apo(a) portion of Lp(a) particles. This conclusion is based on the following experimental observations. The proteinase activity co-migrated with the Lp(a) and apo(a) during their purification from plasma samples from different individuals. The pattern of proteolysis [21] and amidolysis caused either by Lp(a) or apo(a) was clearly different from that caused by either plasmin or kallikrein. Known plasminogen activators had no effect on the activity. In all Lp(a) preparations no kallikrein or Factor Xa could be detected by immunoblotting. Finally, polyclonal antibodies to apo(a) partially inhibited the amidolytic activity of apo(a). These results strongly suggest that Lp(a)/ apo(a) has inherent proteinase activity. As apo(a) occurs in several phenotypes, it will be of interest to study whether all of them have the same degree of serine-proteinase activity. Several studies [41, 42] have demonstrated that Lp(a) is a major constituent of atherosclerotic lesions. Whether the serine-proteinase activity of Lp(a) plays a role in the genesis of atherosclerosis remains to be established.
